Organizing pneumonia following ocrelizumab use in a patient with multiple sclerosis: A case report.

IF 0.7 Q4 RESPIRATORY SYSTEM Tuberkuloz ve Toraks-Tuberculosis and Thorax Pub Date : 2023-03-01 DOI:10.5578/tt.20239913
Nurten Aysan, Gizem Köybaşı, Celal Satıcı, Mustafa Asım Demirkol, Burcu Arpınar Yiğitbaş, Ayşe Filiz Arpaçağ Koşar
{"title":"Organizing pneumonia following ocrelizumab use in a patient with multiple sclerosis: A case report.","authors":"Nurten Aysan, Gizem Köybaşı, Celal Satıcı, Mustafa Asım Demirkol, Burcu Arpınar Yiğitbaş, Ayşe Filiz Arpaçağ Koşar","doi":"10.5578/tt.20239913","DOIUrl":null,"url":null,"abstract":"<p><p>Ocrelizumab is an anti-CD20 monoclonal antibody used in the treatment of primary progressive and relapsing multiple sclerosis (MS). Although cases of organizing pneumonia have been reported in association with other antiCD20 agents such as rituximab, there is insufficient data in the literature on Ocrelizumab-associated lung involvement. Herein, we present a case of organizing pneumonia in a 37-year-old female patient with multiple sclerosis following Ocrelizumab use.</p>","PeriodicalId":45521,"journal":{"name":"Tuberkuloz ve Toraks-Tuberculosis and Thorax","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795250/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberkuloz ve Toraks-Tuberculosis and Thorax","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5578/tt.20239913","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Ocrelizumab is an anti-CD20 monoclonal antibody used in the treatment of primary progressive and relapsing multiple sclerosis (MS). Although cases of organizing pneumonia have been reported in association with other antiCD20 agents such as rituximab, there is insufficient data in the literature on Ocrelizumab-associated lung involvement. Herein, we present a case of organizing pneumonia in a 37-year-old female patient with multiple sclerosis following Ocrelizumab use.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多发性硬化症患者使用奥克立珠单抗后出现的组织性肺炎:病例报告。
Ocrelizumab 是一种抗 CD20 单克隆抗体,用于治疗原发性进展性和复发性多发性硬化症(MS)。虽然已有与其他抗 CD20 药物(如利妥昔单抗)相关的组织化肺炎病例报道,但有关奥克立珠单抗肺部受累的文献数据并不充分。在此,我们介绍了一例 37 岁女性多发性硬化症患者在使用 Ocrelizumab 后出现组织性肺炎的病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.50
自引率
9.10%
发文量
43
期刊最新文献
A patient with widespread skin lesions presenting with massive pleural effusion. A perspective on the scope of videoconferencing-based telemedicine in respiratory diseases outpatient clinic. Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. Analysis of post-COVID symptoms and predisposing factors for chronic post-COVID syndrome. Characteristics of adverse reactions due to subcutaneous allergen immunotherapy applied between 2011-2021: Single center experience.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1